Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273360 | 0.88 | MRGPRX4 (0.70) | MAPTSMN1; SMN2MRGPRX4NPC1RAB9A | |
| SCHEMBL365277 | 0.85 | MRGPRX4 (0.58) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3231604 | 0.84 | MRGPRX4 (0.63) | SMN1; SMN2CYP1A2CYP2C9CYP2C19MRGPRX4 | |
| SCHEMBL692883 | 0.83 | MRGPRX4 (0.66) | MAPTSMN1; SMN2MRGPRX4NPC1RAB9A | |
| SCHEMBL20897506 | 0.82 | MRGPRX4 (0.56) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| Methyl 3-Chloro-4-Methoxybenzoate SCHEMBL1637523 | 0.81 | KMT2A (0.69) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| Methyl 3-Chloro-4-Methoxybenzoate SCHEMBL31296522 | 0.81 | KMT2A (0.69) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10543265 | 0.80 | S1PR4 (0.56) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1398536 | 0.79 | MEN1 (0.59) | MAPTSMN1; SMN2CYP1A2CYP2C19MRGPRX4 | |
| SCHEMBL2801658 | 0.78 | MAPT (0.72) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569725-B2 | 2-[(3-chloro-4-hydroxybenzoyl)amino]-N-[2-(2-methoxyphenyl)ethyl]-5-phenoxybenzamide; therapeutic use as anti-cancer agents, as well as other therapeutic agents, for example, as anti-fertility agents | BRITSOL-MYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569725-B2 | 2-[(3-chloro-4-hydroxybenzoyl)amino]-N-[2-(2-methoxyphenyl)ethyl]-5-phenoxybenzamide; therapeutic use as anti-cancer agents, as well as other therapeutic agents, for example, as anti-fertility agents | BRITSOL-MYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569725-B2 | 2-[(3-chloro-4-hydroxybenzoyl)amino]-N-[2-(2-methoxyphenyl)ethyl]-5-phenoxybenzamide; therapeutic use as anti-cancer agents, as well as other therapeutic agents, for example, as anti-fertility agents | BRITSOL-MYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| US-20060135619-A1 | 2-[(3-chloro-4-hydroxybenzoyl)amino]-N-[2-(2-methoxyphenyl)ethyl]-5-phenoxybenzamide; therapeutic use as anti-cancer agents, as well as other therapeutic agents, for example, as anti-fertility agents | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135619-A1 | 2-[(3-chloro-4-hydroxybenzoyl)amino]-N-[2-(2-methoxyphenyl)ethyl]-5-phenoxybenzamide; therapeutic use as anti-cancer agents, as well as other therapeutic agents, for example, as anti-fertility agents | NASP, BRDT, ACR | MAPT 3634/4885SMN1; SMN2 3983/4885CYP1A2 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.